XT is among the first investors in Israeli startups, partnering with teams that are leading companies with the potential to become market frontrunners.
To date, XT has invested in over 100 companies, including in category leaders such as Duve, Checkmarx, Cymbio, Sofwave, and Phytech.
Udi Angel has been a longtime investor and owner of various multi-billion dollar businesses. His entrepreneurial spirit, vast managerial experience, and personal network continuously contribute to XT Venture Capital's evolution as a leading investor in Israeli technology companies.
Among other activities, he heads several communal and charitable organizations such as “Variety” Children’s Charity Israel (president), and Ruppin Academic Center (chairman of the Board of Governors).
Ori Angel has been active in the technology investment space for years, investing in various categories at both early and growth stages. As a big believer in “technology-led” disruption, he leads the vision of XT Venture Capital and its investment strategy direction.
Among his various activities, Ori is the CEO of XT maritime, a ship-owning company with over 120 employees and 2,500 seamen.
Ori holds a BS in Investment, Finance and Risk Management from London’s City University and MBA from University of Chicago’s Graduate School of Business. He graduated with honors from both institutions.
Lital joined the XT Group in 2013 and serves as its VP HR since 2020, leading the global human capital and all organizational development-related aspects.
Alongside serving as the Group’s VP HR, Lital supports XT Venture Capital and its portfolio companies with various aspects relating to recruitment, retention, welfare, career development, and organizational culture.
Lital holds an MBA and a BA in Economics from the Tel-Aviv University, and is studying for PhD in Business Administration at the Tel-Aviv university.
Bar joined XT Venture Capital in September 2024, where she leads deal sourcing initiatives.
Prior to XT, she spearheaded business development at Pepper (a digital bank by Israel's Leumi Group), driving key growth strategies.
In addition to her corporate roles, Bar founded and led a small-business aid program through the 8200 alumni association, reflecting her entrepreneurial spirit and dedication to supporting local enterprises. Her commitment to social causes is also evident through her ongoing volunteer efforts.
Bar holds a BA in Psychology and Business Administration, and an MBA from Tel Aviv University, where she also served as a teaching assistant.
Assif is a serial entrepreneur at heart, with over twenty years of experience in the software and healthcare industries. After holding various key positions at XT Venture Capital, including heading its Venture Accelerator for several years where he was instrumental in supporting early stage startups from their very beginning, Assif co-founded, headed, and invested in several startups before rejoining XT Venture Capital early 2020.
Currently, Assif is an active board member at Duve and BioT Medical. Notable previous investments include Checkmarx (acquired by Insight Venture Partners), CmyCasa (acquired by Adobe; NASDAQ: ADBE); MentorWave (acquired by Alphabet; NASDAQ: GOOG); and PainReform (NASDAQ: PRFX). In most of these cases, he joined the company at its earliest stages.
Assif holds an LL.M. (negotiation and dispute resolution program) from Bar-Ilan University and an LL.B and BA in Business Administration from The Interdisciplinary Center.
Yoav has been identifying, financing, and growing startup companies for over 20 years. Yoav joined the XT Group after serving as a partner in Yozma Venture Capital, one of Israel's anchor VC funds. Prior to Yozma, Yoav served as a project manager at one of Israel's leading commercial banks.
Yoav is an active board member in select XT Venture Capital portfolio companies, where he leverages an extensive experience and global network to help them achieve their objectives and build value.
Currently, Yoav is serving on the board of Sofwave (TASE: SOFW), Phytech, Epitomee (TASE: EPIT), Cymbio, Healthy.io, Beyeonics, NeuReality, BlueThrone and ZIM (NYSE: ZIM). Previously, Yoav served on the boards of Cognitens (acquired by Hexagon), Kailight Photonics (acquired by Optium), Painreform (Nasdaq: PRFX), and NextNine (acquired by Honeywell).
Yoav holds an MBA from the Haifa University and BSc in Management and Industrial Engineering, cum laude, from the Technion Institute of Technology.
Chen joined XT Venture Capital in 2022 as a Research Analyst, researching categories and trends relevant to XT Venture Capital and its portfolio companies. Prior to joining XT Venture Capital, Chen worked as an Equity Research Analyst at Oppenheimer & Co, analyzing and providing financial insights on publicly traded companies in various industries. Prior to that, Chen was a Hedge Fund Analyst at Clover Wolf Capital.
Chen holds a B.A. in Financial Risk Management and a LL.B. from Reichman University in Herzliya, Israel.
Guy joined XT Group in 2017 as CFO and acts as a board member in some of the Group’s portfolio companies.
In addition to serving as CFO, Guy is involved in XT Venture Capital investment processes and supports financial transactions related to the portfolio companies, including IPOs or M&As.
Before joining XT group, Guy was the CFO of ZIM (NASDAQ: ZIM) for 5 years and prior to that, was CFO of Danya Cebus (Africa Israel Group).
Guy is a certified CPA and holds a BA in Accounting and Economics from the Hebrew University in Jerusalem.
Eyal joined XT Group in 1998 and was appointed General Counsel in 2005.
Alongside serving as the Group’s General Counsel, Eyal acts as in-house legal counsel for XT Venture Capital, taking an integral part in XT Venture Capital's various investments processes.
Eyal possesses extensive experience in finance, commercial, and contract law and holds an LL.B from the University of Sussex in England.
